Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Projects & Grants
Research Output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
22-HEM-19-MSD: A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
Munker, Reinhold
(PI)
Markey Cancer Center / Cancer Research Priority Initiative
Overview
Grants and Contracts Details
Status
Active
Effective start/end date
1/23/23
→
11/2/25
Funding
Merck Sharp & Dohme Corporation:
$37,828.00
View all
View less